TY - JOUR T1 - Cluster and CART analyses identify large subgroups of adults with cystic fibrosis at low risk of 10-year death JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01943-2018 SP - 1801943 AU - Pierre-Régis Burgel AU - Lydie Lemonnier AU - Clémence Dehillotte AU - Jenna Sykes AU - Sanja Stanojevic AU - Anne L. Stephenson AU - Jean-Louis Paillasseur Y1 - 2018/01/01 UR - http://erj.ersjournals.com/content/early/2018/12/14/13993003.01943-2018.abstract N2 - Our goal was to identify subgroups of cystic fibrosis (CF) adults at low risk of death within 10 years.Factor analysis for mixed data followed by Ward's cluster analysis were conducted using 25 variables from 1572 French CF adults in 2005. Rates of death by subgroups were analysed over 10 years. An algorithm was developed using classification and regression tree (CART) to provide rules for the identification of subgroups of CF adults with low rates of death within 10 years. This algorithm was validated in 1376 Canadian CF adults.Seven subgroups were identified by cluster analysis in French CF adults, including two subgroups with low (∼5%) rates of death at 10 years: one subgroup (22% of patients) was composed of patients with non-classic CF, the other subgroup (17% of patients) was composed of patients with classic CF but low rates of P. aeruginosa infection and diabetes. An algorithm based on CART analysis of data in 2005 allowed to identify most French adults with low rates of death. When tested using data from Canadian CF adults in 2005, the algorithm identified 287/1376 (21%) patients at low risk (10-year death, 7.7%).Large subgroups of CF adults share low risk of 10-year mortality.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Burgel reports personal fees from Astra-Zeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GSK, personal fees from Novartis, personal fees from Vertex, personal fees from Zambon, personal fees from MSD, outside the submitted work.Conflict of interest: Dr. Lemonnier has nothing to disclose.Conflict of interest: Ms. Sykes has nothing to disclose.Conflict of interest: Dr. Stanojevic has nothing to disclose.Conflict of interest: Dr. Stephenson reports personal fees from Cystic Fibrosis Canada, outside the submitted work.Conflict of interest: Dr. Paillasseur has nothing to disclose.Conflict of interest: Dr. Dehillotte has nothing to disclose. ER -